Project Grant R03DA055970
Award Date
9/30/23
Completion Date
9/29/24
Dollars Obligated
$218K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Hawaii, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of methamphetamine and cysteinyl leukotrienes in HIV persistence. The research aims to: 1) determine how methamphetamine engages the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 axis to increase HIV infection of CD4+ T-cells and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $552,629 to Temple University to conduct research on the use of chemokine receptor antagonists (CRAs) for treating methamphetamine use disorder (MUD). The research aims to characterize the efficacy of three CRAs (AMD3100, Maraviroc, and R-103) in preclinical models of MUD, evaluating their ability to reduce methamphetamine intake, reinforcing...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This $3,287,052 Cooperative Agreement (Award ID: UG3DA061709) was awarded on May 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports Virogenomics Biodevelopment, Inc., a woman-owned small business, in conducting IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound targeting CD74 receptors as a potential treatment for methamphetamine use disorder. Key activities...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $272,395 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biochemical mechanisms of the G9A/GLP histone methyltransferases and their role in the development of addictive behaviors. The key objectives of this 2-year award, which runs from April 2025 to March 2027, are to: 1) identify specific...
The federal Project Grant award R15DA062968 for $571,675.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a forward genetic screen to identify novel genes involved in the mechanisms of amphetamine action. The research, conducted by Florida Atlantic University, aims to elucidate how amphetamine, a commonly abused psychostimulant, generates addiction by investigating physiological and behavioral modifications...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,481,760 to Emory University to study how methamphetamine (MA) use impacts immune dysfunction in people living with HIV (PWH) on antiretroviral therapy (ART). The 5-year award will leverage existing longitudinal blood samples and collect new blood and cerebrospinal fluid samples to investigate a multi-step process by which MA promotes...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to study the neurogenetic mechanisms underlying nicotine and cannabis addiction. The $175,888 award, effective September 1, 2024 through August 31, 2028, will enable the development of novel transcriptome-connectome analysis methods to identify genes associated with changes in brain functional connectivity related to addiction. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $715,238.00 to the University of California, San Diego (UCSD) to conduct a multivariate genome-wide association analysis of opioid-related traits in a diverse population of 500,000 individuals. The goal is to improve understanding of the genetic basis of opioid use disorder (OUD) and related pre-addiction stages, such as initial opioid use,...